Awakn's decision to exit ketamine healthcare services and focus on R&D of addiction therapies and IP licensing may lead to long-term value for shareholders. The company has signed a non-binding term sheet to license its healthcare services IP and Kare protocol in the UK, and is reviewing its Norwegian healthcare clinics business unit and restructuring its UK clinics. This strategic shift could potentially increase the company's revenue and attract more investors, leading to a positive short-term impact on its stock price.